Trial · NCT00683787
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
NCT00683787, Phase 2, Terminated, Roswell Park Cancer Institute; results first posted 2015-01-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer. Trials, record NCT00683787. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00683787
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
- NCT number
- NCT00683787
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- Roswell Park Cancer Institute
- Conditions
- Gastric Cancer
- Interventions
- docetaxel, vandetanib
- First posted
- 2008-05-23
- Last updated
- 2015-01-08
- Results first posted
- 2015-01-08
- Limitations and caveats
- Due to the study's early termination and inadequate number of patients no statistical inference of the primary and secondary aims were carried forth.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate | 1 year | |
| Secondary | Progression-free Survival | 3 years | |
| Secondary | Overall Survival | 3 years | |
| Secondary | Toxicity | 1 year |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate | 1 year | Due to the study's early termination and inadequate number of patients no statistical inference of the primary and secondary aims were carried forth. | ||
| SECONDARY | Progression-free Survival | 3 years | Due to the study's early termination and inadequate number of patients no statistical inference of the primary and secondary aims were carried forth. | ||
| SECONDARY | Overall Survival | 3 years | Due to the study's early termination and inadequate number of patients no statistical inference of the primary and secondary aims were carried forth. | ||
| SECONDARY | Toxicity | 1 year | Due to the study's early termination and inadequate number of patients no statistical inference of the primary and secondary aims were carried forth. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: Docetaxel | 3 | |
| Overall Study | STARTED | Arm B: Docetaxel+VANDETANIB (100 mg) | 3 | |
| Overall Study | STARTED | Arm C: Docetaxel+VANDETANIB (300 mg) | 2 | |
| Overall Study | COMPLETED | Arm A: Docetaxel | 0 | |
| Overall Study | COMPLETED | Arm B: Docetaxel+VANDETANIB (100 mg) | 0 | |
| Overall Study | COMPLETED | Arm C: Docetaxel+VANDETANIB (300 mg) | 0 | |
| Overall Study | NOT COMPLETED | Arm A: Docetaxel | 3 | |
| Overall Study | NOT COMPLETED | Arm B: Docetaxel+VANDETANIB (100 mg) | 3 | |
| Overall Study | NOT COMPLETED | Arm C: Docetaxel+VANDETANIB (300 mg) | 2 |
Source ClinicalTrials.gov
Adverse events219
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Arm A: Docetaxel | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Arm B: Docetaxel+VANDETANIB (100 mg) | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Arm C: Docetaxel+VANDETANIB (300 mg) | 1 | 2 | 1 |
| other | Leukopenia | Blood and lymphatic system disorders | Arm A: Docetaxel | 1 | 3 | 2 |
| other | Leukopenia | Blood and lymphatic system disorders | Arm B: Docetaxel+VANDETANIB (100 mg) | 2 | 3 | 3 |
| other | Leukopenia | Blood and lymphatic system disorders | Arm C: Docetaxel+VANDETANIB (300 mg) | 1 | 2 | 1 |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm A: Docetaxel | 2 | 3 | 3 |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm B: Docetaxel+VANDETANIB (100 mg) | 2 | 3 | 7 |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm C: Docetaxel+VANDETANIB (300 mg) | 1 | 2 | 1 |
| other | Neutropenia | Blood and lymphatic system disorders | Arm A: Docetaxel | 1 | 3 | 1 |
1 to 10 of 219Source ClinicalTrials.gov
See all 219 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A: Docetaxel | ||
| Total, all-cause mortality | Arm B: Docetaxel+VANDETANIB (100 mg) | ||
| Total, all-cause mortality | Arm C: Docetaxel+VANDETANIB (300 mg) | ||
| Total, other adverse events | Arm A: Docetaxel | 3 | 3 |
| Total, other adverse events | Arm B: Docetaxel+VANDETANIB (100 mg) | 3 | 3 |
| Total, other adverse events | Arm C: Docetaxel+VANDETANIB (300 mg) | 2 | 2 |
| Total, serious adverse events | Arm A: Docetaxel | 1 | 3 |
| Total, serious adverse events | Arm B: Docetaxel+VANDETANIB (100 mg) | 2 | 3 |
| Total, serious adverse events | Arm C: Docetaxel+VANDETANIB (300 mg) | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00683787
GET https://conductscience.org/api/trials/v1/NCT00683787/events?page=2